Orbimed Advisors LLC

Orbimed Advisors LLC has filed trades across 44 companies (mainly through SEC (Form 4)), most often in Passage BIO, Inc., ADARx Pharmaceuticals, Inc. and Sionna Therapeutics, Inc. The record holds 182 filings, for trades running from 7 June 2021 to 28 September 2026.

Both buying and selling appear: 51 purchases worth €179.6M, against 85 sales worth €224.3M. The amount is not disclosed for 5 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 10 share grants and 2 option exercises. 2026 to date brings 12 purchases and 15 sales.

Half of the purchases are above €1.6M and half below. Relative to company size, the median is 1.6% of market cap (7 purchases with a known value). Of 49 purchases, 38 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. After 9 purchases with a full 90-day history, the hit rate stands at 22% and the median 90-day move at -47.0%. Past outcomes like these are no guarantee of what comes next.

Most recently, on 30 September 2026, the filings show an open-market purchase worth €8.8M in ADARx Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.